Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 25, 2008. The report details a specific corporate action regarding a share buyback executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share repurchases.
- Shares Purchased: 2,200,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,128.63 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.12% of total voting rights).
- Shares in Issue: 5,202,082,101 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's share capital through the cancellation of 2,200,000 shares purchased on November 25, 2008. Consequently, the number of shares in issue stands at 5,202,082,101, while the Treasury holding remains at 474,194,158 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming the execution of a share buyback and the resulting capital structure.
Investor Verification Points
- Verify the total number of shares in issue (5,202,082,101) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the Treasury share count (474,194,158) and its percentage of total voting rights (9.12%).
- Note that the 2,200,000 shares purchased were cancelled and are no longer part of the issued share capital.